Abstract
Biologic therapies have notably improved the treatment of RA, making disease remission a realistic goal. After more than ten years of experience, the safety issues associated with these drugs are well characterized and can be avoided with careful patient selection and tight clinical control. Although the different biologic drugs (anti-TNF agents, anti-IL-6, anti-B cells and anti-costimulation of T-cells) have apparently different mechanisms of action, all biologic agents have demonstrated similar efficacy. In addition results of the combination of two biologic therapies have shown no additive clinical effects, although there is an increased risk of infection. Therefore, further research is needed to optimize the use of these and future targeted therapies in RA.
Keywords: Rheumatoid arthritis, biological therapies, clinical response, adverse effects.
Current Topics in Medicinal Chemistry
Title:Biologic Therapy in Rheumatoid Arthritis
Volume: 13 Issue: 6
Author(s): Juan D. Canete and Jose L. Pablos
Affiliation:
Keywords: Rheumatoid arthritis, biological therapies, clinical response, adverse effects.
Abstract: Biologic therapies have notably improved the treatment of RA, making disease remission a realistic goal. After more than ten years of experience, the safety issues associated with these drugs are well characterized and can be avoided with careful patient selection and tight clinical control. Although the different biologic drugs (anti-TNF agents, anti-IL-6, anti-B cells and anti-costimulation of T-cells) have apparently different mechanisms of action, all biologic agents have demonstrated similar efficacy. In addition results of the combination of two biologic therapies have shown no additive clinical effects, although there is an increased risk of infection. Therefore, further research is needed to optimize the use of these and future targeted therapies in RA.
Export Options
About this article
Cite this article as:
Canete Juan D. and Pablos Jose L., Biologic Therapy in Rheumatoid Arthritis, Current Topics in Medicinal Chemistry 2013; 13(6) . https://dx.doi.org/10.2174/15680266113139990093
DOI https://dx.doi.org/10.2174/15680266113139990093 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Hypusine Modification of the Ribosome-binding Protein eIF5A, a Target for New Anti-Inflammatory Drugs: Understanding the Action of the Inhibitor GC7 on a Murine Macrophage Cell Line
Current Pharmaceutical Design Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry An Overview of Nano Delivery Systems for Targeting RNA Interference-based Therapy in Ulcerative Colitis
Current Pharmaceutical Design Biologic Drugs for Analgesia: Redefining the Opportunity
Current Pharmaceutical Biotechnology Tachykinins and the Cardiovascular System
Current Drug Targets Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Medicolegal Aspects of Disclosure of Side Effects of Biologic Drugs in Rheumatology: A Pilot Study
New Emirates Medical Journal PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation
Pharmaceutical Nanotechnology Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs
Current Medicinal Chemistry Emerging Treatment Strategies and Potential Therapeutic Targets in Primary Sjogrens Syndrome
Inflammation & Allergy - Drug Targets (Discontinued) Hashimotos Thyroiditis: From Genes to the Disease
Current Genomics Incidence and Prevention of Thromboembolic Events in One Stage Bilateral Total Hip Arthroplasty: A Systematic Review
Current Vascular Pharmacology Policy and Health Implications of Using the U.S. Food and Drug Administration Product Design Approach in Reducing Tobacco Product Risk
Current Drug Abuse Reviews Understanding and Modulating the Toll Like Receptors (TLRs) and NOD Like Receptors (NLRs) Cross Talk in Type 2 Diabetes
Current Diabetes Reviews Enhancement of Dissolution Profile of Poorly Water Soluble Drugs by Using Techniques of Nanocrystallization
Current Nanomedicine Influence of Gender on C-Reactive Protein, Fibrinogen, and Erythrocyte Sedimentation Rate in Obstructive Sleep Apnea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Strategies and Patent Therapeutics in EBV-Associated Diseases
Mini-Reviews in Medicinal Chemistry